153 related articles for article (PubMed ID: 23121504)
1. Degree of tumor shrinkage following neoadjuvant chemoradiotherapy: a potential predictor for complete pathological response in esophageal cancer?
Voncken FE; Jiang H; Kim J; Guindi M; Brierley J; Knox J; Liu G; Horgan AM; Lister J; Darling G; Metser U; Wong RK
Dis Esophagus; 2014 Aug; 27(6):552-9. PubMed ID: 23121504
[TBL] [Abstract][Full Text] [Related]
2. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
3. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
[TBL] [Abstract][Full Text] [Related]
5. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
6. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Disease Recurrence and Survival in Esophageal Adenocarcinomas With Complete Response to Neoadjuvant Therapy.
Agoston AT; Zheng Y; Bueno R; Lauwers GY; Odze RD; Srivastava A
Am J Surg Pathol; 2015 Aug; 39(8):1085-92. PubMed ID: 26076061
[TBL] [Abstract][Full Text] [Related]
8. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
[TBL] [Abstract][Full Text] [Related]
9. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.
Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP
Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of IgG4+ plasma cell infiltrates following neoadjuvant chemoradiation therapy for esophageal adenocarcinoma.
Yakirevich E; Lu S; Allen D; Mangray S; Fanion JR; Lombardo KA; Safran H; Resnick MB
Hum Pathol; 2017 Aug; 66():126-135. PubMed ID: 28666927
[TBL] [Abstract][Full Text] [Related]
12. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
[TBL] [Abstract][Full Text] [Related]
13. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.
Xi M; Hallemeier CL; Merrell KW; Liao Z; Murphy MAB; Ho L; Hofstetter WL; Mehran R; Lee JH; Bhutani MS; Weston B; Maru DM; Komaki R; Ajani JA; Lin SH
Ann Surg; 2018 Aug; 268(2):289-295. PubMed ID: 28628563
[TBL] [Abstract][Full Text] [Related]
14. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
15. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer.
van Hagen P; Wijnhoven BP; Nafteux P; Moons J; Haustermans K; De Hertogh G; van Lanschot JJ; Lerut T
Br J Surg; 2013 Jan; 100(2):267-73. PubMed ID: 23180560
[TBL] [Abstract][Full Text] [Related]
16. Recurrence patterns and associated factors of locoregional failure following neoadjuvant chemoradiation and surgery for esophageal cancer.
Blackham AU; H Naqvi SM; Schell MJ; Jin W; Gangi A; Almhanna K; Fontaine JP; Hoffe SE; Frakes J; Venkat P; Pimiento JM
J Surg Oncol; 2018 Feb; 117(2):150-159. PubMed ID: 28833197
[TBL] [Abstract][Full Text] [Related]
17. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
19. Outcomes associated with surgery for T4 esophageal cancer.
Pimiento JM; Weber J; Hoffe SE; Shridhar R; Almhanna K; Vignesh S; Karl RC; Meredith KL
Ann Surg Oncol; 2013 Aug; 20(8):2706-12. PubMed ID: 23504118
[TBL] [Abstract][Full Text] [Related]
20. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
